This trial is evaluating whether BLU-451 will improve 4 primary outcomes and 17 secondary outcomes in patients with Antineoplastic Agents. Measurement will happen over the course of Up to 30 months.
This trial requires 150 total participants across 2 different treatment groups
This trial involves 2 different treatments. BLU-451 is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
Respiratory tract cancer presents as a heterogeneous group of malignancies including many different histology. Lung cancer is the most common diagnosis at presentation due to its high prevalence. Although many therapeutic strategies have been adopted over the years, with excellent disease control, it is still associated with unfavorable long term prognosis. In the present study, we have analyzed the clinicopathological features in patients. We have found that some independent prognostic factors are possible factors for better disease-specific survival and good disease control. However, the current therapeutics have failed to cure this disease. Our finding can be used as a basis to develop new therapeutic strategies for these patients in future.
The United States has a significant burden of respiratory tract cancers; therefore, a major public health problem must be considered in light of its potentially high economic costs. The lifetime prevalence of all types of cancer in the United States, combined with their increased incidence in the first decade of life, indicates that the number of cancers diagnosed may escalate rapidly over the next decade.
Neoplasms are a huge and growing risk for people with COPD. Patients with COPD should be informed of the possibility of developing respiratory tract neoplasms. Neoplasms of the lung, esophagus, stomach and cervix should be looked for in COPD. If found, they are treated with the same standard therapies as non-COPD patients.
Respiratory tract neoplasms most commonly develop from basal cell carcinoma, but may appear for many different reasons, each with their own set of risks and treatment options. These include lung cancer due to small-cell lung carcinoma, squamous-cell carcinoma, adenocarcinoma, carcinoid tumors, lepidic-type carcinoid tumors, bronchioloalveolar carcinoma, lung carcinoid tumors, and mixed subtypes.
There is no evidence to indicate a particular treatment for these cancerous (benign) lesions. The primary focus and attention should be directed toward the prevention component, since this is the most plausible avenue that exists for treatment. Tobacco cessation should be aggressively promoted and managed.
Some signs of respiratory tract neoplasms include cough, dyspnea, chest pain, dysphagia, hemoptysis and anemia. Other signs have been described in the literature, but are not as common. Physicians should be aware that multiple signs that are nonspecific, and occur rarely, are helpful.
While several treatments are available to treat respiratory tract tumors, the incidence is still not on the decline in the past decade (1970s). Recent advances in lung-directed radiation therapy are an example of how the field of radiotherapy is slowly making a mark on oncology. The radiopharmaceuticals used for the treatment include yttrium-90 and gallium. While both treatments have shown effectiveness or proof in preliminary investigations, clinical research is still underway to explore whether yttrium and gallium are indeed superior in treating and controlling respiratory tract tumors.
Blu- 451 was well tolerated and significantly improved quality of life in this study. Patients reported significant pain relief and more than 70% reported feeling better. Data from a recent study further support the use of Blu- 451 in patients with respiratory tract neoplasms, including those with SCC.
It seems that there is a better understanding of respiratory tract tumors and that appropriate endoscopic, imaging, and histopathologic correlation may improve treatment outcomes. Clinical trials should be more aggressive in trials for sarcomas and nonsmall cell lung carcinomas, if they can be justified. Lung cancer trials might be warranted in small non-[small cell lung cancer](https://www.withpower.com/clinical-trials/small-cell-lung-cancer) and lung metastases of small cell lung cancer, although with limited results.
Blu-451 provides a novel mechanism for antiangiogenic activity by inducing autophagy/macrophages apoptosis and microvesicles shedding. Blu-451 may have a potential utility in anti-cancer therapy. The antitumor activity may be due to its antiangiogenic role.
In a recent study, findings demonstrates a significant change in the overall survival rate of our patients when they were switched to the use of 5-FU and CDDP. This change of combination was not attributed to the change in chemotherapeutic regimens used.
Oral administration of BTX-A was not associated with any adverse events in a group of subjects with moderate to severe allergic asthma, and no clinical or laboratory tests (i.e., blood counts, clotting tests, and urinalysis) showed any significant changes. Thus, BTX-A is a safe, effective topical treatment in people with moderate to severe allergic asthma and is therefore suitable for studies in such individuals.